Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Mercury Biopharmaceutical OCF Yield % Related Terms
Mercury Biopharmaceutical OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercury Biopharmaceutical (ROCO:6932) has a OCF Yield % of -2.00 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Mercury Biopharmaceutical and its competitors. According to the industry distribution chart, Mercury Biopharmaceutical ranks #766 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 76.1%.
Is Mercury Biopharmaceutical's OCF Yield % too high?
Mercury Biopharmaceutical's current OCF Yield % is -2.00. Based on the distribution chart, Mercury Biopharmaceutical ranks #766 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #766 out of 1007 companies for OCF Yield %. This places Mercury Biopharmaceutical in the lower half of its industry. The industry median OCF Yield % is 3.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Mercury Biopharmaceutical and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Biopharmaceutical's current OCF Yield % is -2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.93 — trading 83.5% below its estimated fair value. The current OCF Yield % is -2.00. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current OCF Yield % is -2.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.93 is trading 83.5% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
OCF Yield %: -2.00
GF Value™: NT$36.00 vs. price of NT$5.93 (83.5% below fair value)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score
Get the complete analysis for ROCO:6932
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
